• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

植物表达的非洲马瘟病毒样颗粒的免疫原性:对新型疫苗的启示。

Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine.

机构信息

Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa.

Equine Research Centre, University of Pretoria, Onderstepoort, South Africa.

出版信息

Plant Biotechnol J. 2018 Feb;16(2):442-450. doi: 10.1111/pbi.12783. Epub 2017 Aug 1.

DOI:10.1111/pbi.12783
PMID:28650085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5787833/
Abstract

African horse sickness (AHS) is a debilitating and often fatal viral disease affecting horses in much of Africa, caused by the dsRNA orbivirus African horse sickness virus (AHSV). Vaccination remains the single most effective weapon in combatting AHS, as there is no treatment for the disease apart from good animal husbandry. However, the only commercially available vaccine is a live-attenuated version of the virus (LAV). The threat of outbreaks of the disease outside its endemic region and the fact that the LAV is not licensed for use elsewhere in the world, have spurred attempts to develop an alternative safer, yet cost-effective recombinant vaccine. Here, we report the plant-based production of a virus-like particle (VLP) AHSV serotype five candidate vaccine by Agrobacterium tumefaciens-mediated transient expression of all four capsid proteins in Nicotiana benthamiana using the cowpea mosaic virus-based HyperTrans (CPMV-HT) and associated pEAQ plant expression vector system. The production process is fast and simple, scalable, economically viable, and most importantly, guinea pig antiserum raised against the vaccine was shown to neutralize live virus in cell-based assays. To our knowledge, this is the first report of AHSV VLPs produced in plants, which has important implications for the containment of, and fight against the spread of, this deadly disease.

摘要

非洲马瘟(AHS)是一种在非洲大部分地区影响马匹的严重且常常致命的病毒性疾病,由 dsRNA 呼肠孤病毒非洲马瘟病毒(AHSV)引起。除了良好的动物饲养管理外,疫苗接种仍然是对抗 AHS 的最有效手段之一,因为这种疾病没有治疗方法。然而,唯一可商购的疫苗是该病毒的减毒活版本(LAV)。该疾病在其流行地区以外爆发的威胁以及 LAV 未在世界其他地区获得许可使用的事实,促使人们试图开发替代的更安全但具有成本效益的重组疫苗。在这里,我们报告了通过农杆菌介导的瞬时表达在 Nicotiana benthamiana 中生产 AHSV 血清型五型候选疫苗的病毒样颗粒(VLP),使用基于豇豆花叶病毒的 HyperTrans(CPMV-HT)和相关的 pEAQ 植物表达载体系统表达所有四个衣壳蛋白。该生产过程快速、简单、可扩展、经济可行,最重要的是,针对疫苗产生的豚鼠抗血清在基于细胞的测定中显示出中和活病毒的能力。据我们所知,这是首次在植物中生产 AHSV VLP,这对控制和对抗这种致命疾病的传播具有重要意义。

相似文献

1
Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine.植物表达的非洲马瘟病毒样颗粒的免疫原性:对新型疫苗的启示。
Plant Biotechnol J. 2018 Feb;16(2):442-450. doi: 10.1111/pbi.12783. Epub 2017 Aug 1.
2
Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.植物源嵌合病毒样颗粒——一种针对非洲马瘟的新一代疫苗。
BMC Vet Res. 2019 Dec 3;15(1):432. doi: 10.1186/s12917-019-2184-2.
3
Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses.植物源非洲马瘟病毒样颗粒在马中的安全性和免疫原性。
Vet Res. 2018 Oct 11;49(1):105. doi: 10.1186/s13567-018-0600-4.
4
VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.用于非洲马瘟病毒(AHSV)的失活感染性单动物疫苗候选物研发中AHSV的VP2交换和NS3/NS3a缺失
J Virol. 2015 Sep;89(17):8764-72. doi: 10.1128/JVI.01052-15. Epub 2015 Jun 10.
5
Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.用表达单一非洲马瘟病毒VP2抗原的重组改良安卡拉痘苗(MVA)病毒进行疫苗接种时,联合给药可在马体内诱导产生交叉反应性病毒中和抗体(VNAb)。
Vaccine. 2017 Oct 20;35(44):6024-6029. doi: 10.1016/j.vaccine.2017.04.005. Epub 2017 Apr 21.
6
African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.非洲马瘟病毒(AHSV)在 NS3/NS3a 蛋白中缺失 77 个氨基酸后不具有毒力,是一种安全有希望的非洲马瘟失能感染性单头动物(DISA)疫苗平台。
Vaccine. 2018 Apr 5;36(15):1925-1933. doi: 10.1016/j.vaccine.2018.03.003. Epub 2018 Mar 7.
7
The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.基于表达非洲马瘟病毒 VP2 抗原的改良安卡拉痘苗病毒(MVA)的重组疫苗的免疫原性取决于递送到宿主的表达 VP2 蛋白的水平。
Antiviral Res. 2018 Jun;154:132-139. doi: 10.1016/j.antiviral.2018.04.015. Epub 2018 Apr 18.
8
Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants.不同佐剂的灭活非洲马瘟疫苗的安全性和有效性。
Vaccine. 2020 Oct 21;38(45):7108-7117. doi: 10.1016/j.vaccine.2020.08.072. Epub 2020 Sep 10.
9
Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR mice.植物表达的马传染性贫血病毒 5 型嵌合病毒样颗粒(VLPs)和病毒蛋白 2(VP2)疫苗在 IFNAR 小鼠中的保护性免疫。
Vaccine. 2022 Aug 19;40(35):5160-5169. doi: 10.1016/j.vaccine.2022.06.079. Epub 2022 Jul 25.
10
Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine.用市售多价减毒活疫苗免疫马匹后非洲马瘟病毒核酸及抗体的动态变化
Vaccine. 2017 Apr 25;35(18):2504-2510. doi: 10.1016/j.vaccine.2017.03.005. Epub 2017 Mar 22.

引用本文的文献

1
Development of an African horse sickness VP6 DIVA diagnostic ELISA.一种非洲马瘟病毒VP6鉴别诊断ELISA的开发。
Virol J. 2025 Aug 12;22(1):276. doi: 10.1186/s12985-025-02898-1.
2
Virus-like Particles Produced in Plants: A Promising Platform for Recombinant Vaccine Development.植物中产生的病毒样颗粒:重组疫苗开发的一个有前景的平台。
Plants (Basel). 2024 Dec 20;13(24):3564. doi: 10.3390/plants13243564.
3
Getting Hold of the Tobamovirus Particle-Why and How? Purification Routes over Time and a New Customizable Approach.获得烟草花叶病毒粒子——为什么以及如何?随着时间的推移的纯化途径和一种新的可定制方法。

本文引用的文献

1
Transient Bluetongue virus serotype 8 capsid protein expression in .蓝舌病病毒血清型8衣壳蛋白在……中的瞬时表达
Biotechnol Rep (Amst). 2015 Dec 7;9:15-24. doi: 10.1016/j.btre.2015.12.001. eCollection 2016 Mar.
2
Analysis of the three-dimensional structure of the African horse sickness virus VP7 trimer by homology modelling.通过同源建模分析非洲马瘟病毒VP7三聚体的三维结构。
Virus Res. 2017 Mar 15;232:80-95. doi: 10.1016/j.virusres.2017.02.001. Epub 2017 Feb 3.
3
Synthetic plant virology for nanobiotechnology and nanomedicine.
Viruses. 2024 May 30;16(6):884. doi: 10.3390/v16060884.
4
The Potential of Plant-Produced Virus-like Particle Vaccines for African Horse Sickness and Other Equine Orbiviruses.植物生产的病毒样颗粒疫苗用于非洲马瘟和其他马环状病毒的潜力
Pathogens. 2024 May 28;13(6):458. doi: 10.3390/pathogens13060458.
5
Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice.在 IFNAR-/- 小鼠中植物生产的九价非洲马瘟病毒蛋白 2(VP2)疫苗的免疫原性特征。
PLoS One. 2024 Apr 16;19(4):e0301340. doi: 10.1371/journal.pone.0301340. eCollection 2024.
6
Plant-based biopharmaceutical engineering.基于植物的生物制药工程
Nat Rev Bioeng. 2023;1(6):426-439. doi: 10.1038/s44222-023-00044-6. Epub 2023 Mar 21.
7
Virus-like Particle Vaccines and Platforms for Vaccine Development.病毒样颗粒疫苗及其疫苗开发平台。
Viruses. 2023 May 2;15(5):1109. doi: 10.3390/v15051109.
8
Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.基于纳米颗粒和微粒的针对具有兽医重要性的环状病毒的疫苗
Vaccines (Basel). 2022 Jul 14;10(7):1124. doi: 10.3390/vaccines10071124.
9
Microparticles and Nanoparticles from Plants-The Benefits of Bioencapsulation.植物来源的微粒和纳米颗粒——生物包封的益处
Vaccines (Basel). 2021 Apr 11;9(4):369. doi: 10.3390/vaccines9040369.
10
Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.病毒样颗粒:制备、免疫原性及其作为纳米疫苗和药物纳米载体的作用。
J Nanobiotechnology. 2021 Feb 25;19(1):59. doi: 10.1186/s12951-021-00806-7.
用于纳米生物技术和纳米医学的合成植物病毒学。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jul;9(4). doi: 10.1002/wnan.1447. Epub 2017 Jan 11.
4
Plant-produced biopharmaceuticals: A case of technical developments driving clinical deployment.植物生产的生物制药:技术发展推动临床应用的案例。
Science. 2016 Sep 16;353(6305):1237-40. doi: 10.1126/science.aaf6638.
5
African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004-2014.2004 - 2014年南非由基因组重配和减毒活疫苗病毒毒力返强导致的非洲马瘟
Emerg Infect Dis. 2016 Dec;22(12):2087-2096. doi: 10.3201/eid2212.160718. Epub 2016 Dec 15.
6
Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.无复制能力的非洲马瘟病毒颗粒的组装:针对所有血清型的疫苗合理设计
J Virol. 2016 Jul 27;90(16):7405-7414. doi: 10.1128/JVI.00548-16. Print 2016 Aug 15.
7
The case for plant-made veterinary immunotherapeutics.植物源兽用免疫治疗剂的应用前景。
Biotechnol Adv. 2016 Sep-Oct;34(5):597-604. doi: 10.1016/j.biotechadv.2016.02.007. Epub 2016 Feb 12.
8
Synthesis of empty african horse sickness virus particles.空非洲马瘟病毒粒子的合成。
Virus Res. 2016 Feb 2;213:184-194. doi: 10.1016/j.virusres.2015.12.006. Epub 2015 Dec 10.
9
VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.用于非洲马瘟病毒(AHSV)的失活感染性单动物疫苗候选物研发中AHSV的VP2交换和NS3/NS3a缺失
J Virol. 2015 Sep;89(17):8764-72. doi: 10.1128/JVI.01052-15. Epub 2015 Jun 10.
10
Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.用表达非洲马瘟病毒(AHSV)VP2的改良安卡拉痘苗病毒免疫的小鼠所产生的抗血清,在攻毒前48小时或攻毒后48小时给予时可提供保护。
Antiviral Res. 2015 Apr;116:27-33. doi: 10.1016/j.antiviral.2015.01.009. Epub 2015 Jan 30.